INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2024 Financial Results and Recent Business Highlights
BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgical treatment for recurrent respiratory papillomatosis (RRP) Planni